These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25851859)

  • 1. Dinutuximab approved for high-risk neuroblastoma.
    Cancer Discov; 2015 Jun; 5(6):OF5. PubMed ID: 25851859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dinutuximab: first global approval.
    Dhillon S
    Drugs; 2015 May; 75(8):923-7. PubMed ID: 25940913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When Life Expectancy is Not Short Enough: A Perspective on the National Institute for Health and Care Excellence (NICE) Preliminary Guidance for Dinutuximab.
    Adamson PC; Park JR; Pearson AD
    Pediatr Blood Cancer; 2016 Jun; 63(6):962-3. PubMed ID: 26740172
    [No Abstract]   [Full Text] [Related]  

  • 4. Restricting Access to Hope: A Parent's Perspective on the National Institute for Health and Care Excellence (NICE) Preliminary Guidance for Dinutuximab.
    Bernstein J
    Pediatr Blood Cancer; 2016 Jun; 63(6):964-5. PubMed ID: 26918436
    [No Abstract]   [Full Text] [Related]  

  • 5. Dinutuximab for maintenance therapy in pediatric neuroblastoma.
    McGinty L; Kolesar J
    Am J Health Syst Pharm; 2017 Apr; 74(8):563-567. PubMed ID: 28389455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
    Mora J
    Expert Rev Clin Pharmacol; 2016; 9(5):647-53. PubMed ID: 26934530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In brief: Dinutuximab (Unituxin) for high-risk neuroblastoma.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):e48. PubMed ID: 27027692
    [No Abstract]   [Full Text] [Related]  

  • 8. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.
    Ploessl C; Pan A; Maples KT; Lowe DK
    Ann Pharmacother; 2016 May; 50(5):416-22. PubMed ID: 26917818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dinutuximab: A Review in High-Risk Neuroblastoma.
    Hoy SM
    Target Oncol; 2016 Apr; 11(2):247-53. PubMed ID: 26891967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA accelerated approval benefits glioblastoma.
    Cloughesy T
    Lancet Oncol; 2010 Dec; 11(12):1120. PubMed ID: 21126686
    [No Abstract]   [Full Text] [Related]  

  • 11. Nivolumab approved for lung cancer.
    Cancer Discov; 2015 May; 5(5):OF1. PubMed ID: 25835401
    [No Abstract]   [Full Text] [Related]  

  • 12. Dinutuximab for the treatment of pediatric patients with neuroblastoma.
    Greenwood K; Foster JH
    Drugs Today (Barc); 2017 Sep; 53(9):469-476. PubMed ID: 29238760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibody approved for metastatic breast cancer.
    Oncology (Williston Park); 1998 Dec; 12(12):1727. PubMed ID: 9874846
    [No Abstract]   [Full Text] [Related]  

  • 14. Approved monoclonal antibodies for cancer therapy.
    Boyiadzis M; Foon KA
    Expert Opin Biol Ther; 2008 Aug; 8(8):1151-8. PubMed ID: 18613766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety of dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
    Greenwood KL; Foster JH
    Expert Opin Drug Saf; 2018 Dec; 17(12):1257-1262. PubMed ID: 30433831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction Chemotherapy With an Anti-GD2 Monoclonal Antibody (Dinutuximab) and Cytokines in Children With Newly Diagnosed High-risk Neuroblastoma: A Case Series.
    Gartrell J; Shulkin BL; Helmig S; Caldwell KJ; Furman W; Federico SM
    J Pediatr Hematol Oncol; 2021 Jul; 43(5):e692-e696. PubMed ID: 33181583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy.
    Secola R; Marachelian A; Cohn SL; Toy B; Neville K; Granger M; Brentlinger A; Martin G
    J Pediatr Oncol Nurs; 2017; 34(3):160-172. PubMed ID: 28061552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation of immunotherapy into the treatment of neuroblastoma - single center experience with the administration of dinutuximab and management of its adverse effects.
    Achbergerová M; Hederová S; Mikesková M; Husáková K; Hrašková A; Kolenová A
    Klin Onkol; 2020; 33(5):372-378. PubMed ID: 33108882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
    Parsons K; Bernhardt B; Strickland B
    Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic monoclonal antibodies: trends in development and approval in the US.
    Reichert JM
    Curr Opin Mol Ther; 2002 Apr; 4(2):110-8. PubMed ID: 12044031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.